Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Most people in a pilot program at a safety-net HIV clinic achieved viral suppression on the long-acting injectable regimen.
Generic cabotegravir, an every-other-month injectable to prevent HIV, will arrive in select countries. WHO and Health Gap have opinions.
Under provisions of the Affordable Care Act, insurers must cover costs related to PrEP.
The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.
The every-other-month schedule of injectable cabotegravir plus rilpivirine enables some people to take HIV treatment just six times a year.
Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.
Every-other-month cabotegravir injections may work even better than daily pills for HIV prevention.
Starting today, the CDC recommends that clinicians prescribe pre-exposure prophylaxis to anyone who asks for it.
The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.
According to a recent study, transgender women might benefit more than they think from the prevention pill.
Injections given every month or every other month were preferred over daily pills.
Monthly islatravir pills are just one of the long-acting options in the HIV prevention pipeline.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.